Astria Therapeutics, Inc. (ATXS)
Company Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching.
The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021.
Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Country | United States |
Founded | 2008 |
IPO Date | Jun 25, 2015 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 59 |
CEO | Ms. Jill C. Milne Ph.D. |
Contact Details
Address: 75 State Street, Suite 1400 Boston, Massachusetts 02109 United States | |
Phone | 617-349-1971 |
Website | astriatx.com |
Stock Details
Ticker Symbol | ATXS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001454789 |
CUSIP Number | 04635X102 |
ISIN Number | US04635X1028 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Jill C. Milne Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
Benjamin S. Harshbarger J.D. | Chief Legal Officer |
Noah C. Clauser CPA | Chief Financial Officer and Treasurer |
Keri McGrail | Senior Vice President of Human Resources |
Andrea L. Matthews | Chief Business Officer |
Andrew A. Komjathy | Chief Commercial Officer |
Dr. Christopher J. Morabito M.D. | Chief Medical Officer |
John Ruesch | Senior Vice President of Pharmaceutical Sciences and Technical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 25, 2024 | 8-K | Current Report |
Mar 11, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Mar 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Mar 4, 2024 | 8-K | Current Report |
Mar 4, 2024 | 424B5 | Filing |
Mar 4, 2024 | 10-K | Annual Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |